■生物制剂已经彻底改变了斑块状银屑病的管理,并且正在蓬勃发展。我们旨在通过文献计量学构建该领域的知识结构,分析研究趋势和前沿热点,以激发未来的研究方向,为临床决策提供有价值的参考。
■搜索了2004年至2023年WebofScience数据库核心集合中有关斑块状牛皮癣的生物制剂的出版物。使用R进行了文献计量分析和科学知识图谱,CiteSpace,和VOSviewer软件。
■由来自67个国家的9,474名作者撰写的2,672篇文章被纳入研究。在过去的20年中,年度出版物的数量稳步增加。最多产的国家,机构,作者是美国,诺华,和教授。ReickK.,分别。参考分析将该领域的研究基础分为10个主要集群。“功效”和“安全性”是最常见的关键词,聚类分析将这一领域的研究分为四组。突发检测捕获了当前的热门关键词,包括白细胞介素(IL)-17抑制剂,IL-23抑制剂,“药物生存,\"\"停止,\"\"Covid-19,\"\"现实世界,“和”临床特征。
■在过去的二十年中,关于斑块型银屑病生物制剂研究的全球出版物稳步增长。有效性和安全性是研究人员最关心的话题,和IL-17抑制剂,IL-23抑制剂,真实世界的研究,疗效预测,生物制剂失效或停药后的再治疗是当前的研究热点。
UNASSIGNED: Biologics have revolutionized the management of plaque psoriasis and are flourishing. We aimed to construct a knowledge structure in this field through bibliometrics, analyze research trends and cutting-edge hotspots to inspire future research directions, and provide valuable references for clinical decisions.
UNASSIGNED: Publications on biologics for plaque psoriasis in the Web of Science database core collection from 2004 to 2023 were searched. Bibliometric analysis and scientific knowledge mapping were performed with R, CiteSpace, and VOSviewer software.
UNASSIGNED: 2,672 articles written by 9,474 authors from 67 countries were included in the study. The number of annual publications has steadily increased over the last 20 years. The most prolific countries, institutions, and authors were the United States, Novartis, and Prof. Reick K., respectively. Reference analysis categorized the research base of the field into 10 main clusters. \"Efficacy\" and \"safety\" were the most frequent keywords, and cluster analysis categorized the research in this area into four groups. Burst detection captured current hot keywords including interleukin (IL)-17 inhibitors, IL-23 inhibitors, \"drug survival,\" \"discontinuation,\" \"Covid-19,\" \"real-world,\" and \"clinical features.\"
UNASSIGNED: Global publications on biologics research in plaque psoriasis have grown steadily and rapidly over the past two decades. Efficacy and safety are the highest topics of concern for researchers, and IL-17 inhibitors, IL-23 inhibitors, real-world studies, efficacy prediction, and retreatment after biologics failure or discontinuation are current research hotspots.